Uso de vericiguat en pacientes con falla cardiaca y fracción de eyección reducida

Edvin Méndez

doi:10.36314/cunori.v7i2.233

Authors

Edvin Méndez Universidad de San Carlos de Guatemala

DOI:

https://doi.org/10.36314/cunori.v7i2.233

Keywords:

vericiguat, pharmacological, mortality, reduced, cardiovascular

Abstract

PROBLEM: the population with heart failure represents a high rate of hospital admissions, mortality and cardiovascular events in all developed and underdeveloped countries. The therapy of these has evolved a lot in the last decades, but despite this, patients who suffer multiple events secondary to this pathology are always appreciated. The new pharmacological treatments represent a feasible alternative for those patients who present worsening despite having a target treatment, dictated by the latest heart failure treatment guidelines. OBJECTIVE: to describe the use of vericiguat in patients with heart failure and reduced ejection fraction. MATERIAL AND METHODS: for the development of the study, a bibliographic review was carried out, based on primary sources, in which scientific articles and meta-analyses were taken into account. CONCLUSION: Among the main beneficial effects of vericiguat, it was evidenced that the primary events of cardiovascular death and first hospitalization were lower in patients with heart failure with reduced ejection fraction; which also proved to be safe in patients regardless of their initial renal function, not showing complications or deterioration of the same during its use and it also proved to maintain its effectiveness in patients with atrial fibrillation.

Downloads

Download data is not yet available.

Author Biography

Edvin Méndez, Universidad de San Carlos de Guatemala

Undergraduate student of the Physician and Surgeon career belonging to the Centro Universitario de Oriente of the University of San Carlos of Guatemala. With participation in undergraduate research carried out in the hospital area of the departments of Internal Medicine, Surgery, Gynecology, Pediatrics, as well as during the Supervised Professional Practice.

References

Butler, J., Stebbins, A., Melenovský, V., Sweitzer, N. K., Cowie, M. R., Stehlik, J., Khan, M. S., Blaustein, R. O., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., Nkulikiyinka, R., O’Connor, C. M., Pieske, B. M., Ponikowski, P., Spertus, J. A., Voors, A. A., Anstrom, K. J., & Armstrong, P. W. (2022). Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. Circulation. Heart Failure, 15(6), E009337. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009337 DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.121.009337

Follmann, M., Ackerstaff, J., Redlich, G., Wunder, F., Lang, D., Kern, A., Fey, P., Griebenow, N., Kroh, W., Becker-Pelster, E. M., Kretschmer, A., Geiss, V., Li, V., Straub, A., Mittendorf, J., Jautelat, R., Schirok, H., Schlemmer, K. H., Lustig, K., … Stasch, J. P. (2017). Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. Journal of Medicinal Chemistry, 60(12), 5146–5161. https://doi.org/10.1021/ACS.JMEDCHEM.7B00449/SUPPL_FILE/JM7B00449_SI_002.CSV DOI: https://doi.org/10.1021/acs.jmedchem.7b00449

Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., Samano, E. T., Muller, K., Roessig, L., & Pieske, B. (2015). Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA, 314(21), 2251–2262. https://doi.org/10.1001/JAMA.2015.15734 DOI: https://doi.org/10.1001/jama.2015.15734

Gheorghiade, M., Marti, C. N., Sabbah, H. N., Roessig, L., Greene, S. J., Böhm, M., Burnett, J. C., Campia, U., Cleland, J. G. F., Collins, S. P., Fonarow, G. C., Levy, P. D., Metra, M., Pitt, B., Ponikowski, P., Sato, N., Voors, A. A., Stasch, J. P., & Butler, J. (2013). Soluble guanylate cyclase: A potential therapeutic target for heart failure. Heart Failure Reviews, 18(2), 123–134. https://doi.org/10.1007/S10741-012-9323-1/METRICS DOI: https://doi.org/10.1007/s10741-012-9323-1

González-Juanatey, J. R., Anguita-Sánchez, M., Bayes-Genís, A., Comín-Colet, J., García-Quintana, A., Recio-Mayoral, A., Zamorano-Gómez, J. L., Cepeda-Rodrigo, J. M., & Manzano, L. (2022). Vericiguat en insuficiencia cardíaca: de la evidencia científica a la práctica clínica. Revista Clínica Española, 222(6), 359–369. https://doi.org/10.1016/j.rce.2021.12.005 DOI: https://doi.org/10.1016/j.rce.2021.12.005

Gustavo, I.-C., Juan Ramón, H.-G., Roció Milagro, L.-L., José Manuel, O.-A., René, V.-M., & Valenzuela Alibe Natanai, P. (2021). Insuficiencia cardiaca crónica con fracción de eyección reducida: abordaje teórico, clínico y terapéutico. Chronic heart failure with reduced ejection fraction: theoretical, clini-cal and therapeutic approach. REVMEDUAS 333 Rev Med UAS, 11(4), 7191–9895. https://doi.org/10.28960/revmeduas.2007-8013.v11.n4.008 DOI: https://doi.org/10.28960/revmeduas.2007-8013.v11.n4.008

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., … Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012 DOI: https://doi.org/10.1016/j.jacc.2021.12.012

Hussain, A., Misra, A., & Bozkurt, B. (2022). Endpoints in Heart Failure Drug Development. Cardiac Failure Review, 8. https://doi.org/10.15420/CFR.2021.13 DOI: https://doi.org/10.15420/cfr.2021.13

Pieske, B., Patel, M. J., Westerhout, C. M., Anstrom, K. J., Butler, J., Ezekowitz, J., Hernandez, A. F., Koglin, J., Lam, C. S. P., Ponikowski, P., Roessig, L., Voors, A. A., O’Connor, C. M., & Armstrong, P. W. (2019). Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. European Journal of Heart Failure, 21(12), 1596–1604. https://doi.org/10.1002/EJHF.1664 DOI: https://doi.org/10.1002/ejhf.1664

Ponikowski, P., Alemayehu, W., Oto, A., Bahit, M. C., Noori, E., Patel, M. J., Butler, J., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., O’Connor, C. M., Pieske, B., Roessig, L., Voors, A. A., Westerhout, C., & Armstrong, P. W. (2021). Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. European Journal of Heart Failure, 23(8), 1300–1312. https://doi.org/10.1002/EJHF.2285 DOI: https://doi.org/10.1002/ejhf.2285

Rodríguez-Artalejo, F., Banegas Banegas, J. R., & Guallar-Castillón, P. (2004). Epidemiología de la insuficiencia cardíaca. Revista Española de Cardiología, 57(2), 163–170. https://doi.org/10.1157/13057268 DOI: https://doi.org/10.1016/S0300-8932(04)77080-3

Roth, G. A., Forouzanfar, M. H., Moran, A. E., Barber, R., Nguyen, G., Feigin, V. L., Naghavi, M., Mensah, G. A., & Murray, C. J. L. (2015). Demographic and Epidemiologic Drivers of Global Cardiovascular Mortality. New England Journal of Medicine, 372(14), 1333–1341. https://doi.org/10.1056/nejmoa1406656 DOI: https://doi.org/10.1056/NEJMoa1406656